Drug Discovery World

JULY 2, 2024

Many of the more recent companies to launch in Switzerland have grown out of, developed assets from, or received financial support from the established pharmaceutical corporations in the country. In 2005, Glycart was acquired by the Roche Group and integrated in Roche Pharma Research and Early Development (pRED).

Science 147

Science Drugs Clinical Trials Licensing 147

The Pharma Data

JANUARY 6, 2021

He continues: “With the green light granted by the FDA to continue our clinical research, we are one step closer to offering psoriasis patients a novel, improved oral treatment option and thereby enhancing their quality of life. UNION is headquartered in Hellerup ( Denmark ) and is managed by an experienced international team.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. PLYMOUTH MEETING, Pa.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52

The Pharma Data

JULY 8, 2021

is a leading global pharmaceutical company headquartered in Japan. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter , LinkedIn , Facebook , YouTube. About Eisai Co.,

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

JANUARY 24, 2021

Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. Food and Drug Administration (“FDA”) approval. Toronto, Ontario–(Newsfile Corp.

FDA 52

FDA Drugs Clinical Development Pharmaceutical Companies 52

The Pharma Data

DECEMBER 8, 2020

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. The company’s goal is focused on improving outcomes for cancer patients by harnessing the power of targeted radioisotopes. SciNeuro Pharmaceuticals .

RNA 52

RNA Protein Expression Therapies Disease 52

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

AUGUST 10, 2023

Achieve Life Sciences is a specialty pharmaceutical company committed to addressing the global smoking health and nicotine addiction epidemic through the development and commercialisation of cytisinicline. As such, the company has achieved some key milestones this year.

FDA Approval 130

FDA Approval Clinical Trials Drugs FDA 130

The Pharma Data

DECEMBER 8, 2020

Orphan drug designation is the first step in receiving orphan drug exclusivity following approval, which confers seven years of market exclusivity for the relevant indication. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. Forward-looking Statements.

FDA 40

FDA Treatment FDA Approval Drugs 40

Drug Discovery World

SEPTEMBER 16, 2022

Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. . million facility in Durham North Carolina to support the company’s gene therapy capabilities.

Therapies 130

Therapies Clinical Trials Production Trials 130

The Connected Lab

APRIL 8, 2020

For patients suffering from an illness with no approved treatment, the wait can be unnerving. To this day, more than 400 million people suffer from rare diseases and 95% of rare diseases lack an FDA approved treatment 3. Companies such as Celgene, GSK, Sanofi, and Sunovion have partnered with Exscientia to solve this problem.

Pharma Companies 52

Pharma Companies Laboratories FDA Approval Drugs 52

Codon

MARCH 24, 2024

” Even today, the company’s profile on the Flagship Pioneering website knocks the size of “pharmaceutical factories,” which “can run to 800,000 square feet or more,” and touts the beauty of cells as factories, with messenger RNA as their “foreman.” The real cost is clinical development.

Engineering 85

Engineering Vaccine Production RNA 85

The Pharma Data

JUNE 26, 2021

Application seeks two pediatric indications, including an age-appropriate new weight-based oral suspension formulation to help minimize dosing errors If approved, XARELTO ® will be the first and only oral Factor Xa inhibitor indicated in the U.S. Food and Drug Administration (FDA) for the use of XARELTO ® (rivaroxaban) in pediatric patients.

Doctors 52

Doctors Hospitals Clinical Trials Treatment 52

The Pharma Data

OCTOBER 28, 2020

OSAKA, Japan–( BUSINESS WIRE )– Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced financial results for the first half of fiscal year 2020 (period ended September 30, 2020). 29, 2020 06:19 UTC. Press release ). Press release ). Press release ). Press release ).

Pharmaceutical Companies 40

Pharmaceutical Companies Engineering Therapies Clinical Trials 40

The Pharma Data

DECEMBER 29, 2020

” The Phase III clinical development program consists of three studies, the BRIDGE study, the BALANCE study and the BRIGHT study. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc.

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52